ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The current first-line standard of care for CML patients is treatment with tyrosine kinase inhibitors (TKIs) that competitively or allosterically inhibit p210BCR-ABL1, as well as other BCR::ABL1 variants, although less effectively [2,20,21,22].